Results 21 to 30 of about 86,542 (275)
Microorganism-Derived Molecules as Enzyme Inhibitors to Target Alzheimer’s Diseases Pathways
Pharmaceuticals, 2023 Alzheimer’s disease (AD) is the most common form of dementia. It increases the risk of other serious diseases and causes a huge impact on individuals, families, and socioeconomics.
Thi Hanh Nguyen +2 more
doaj +1 more source
Membrane protein secretases [PDF]
Biochemical Journal, 1997 A diverse range of membrane proteins of Type I or Type II topology also occur as a circulating, soluble form. These soluble forms are often derived from the membrane form by proteolysis by a group of enzymes referred to collectively as ‘secretases‘ or ‘sheddases’.
N M, Hooper, E H, Karran, A J, Turner
openaire +2 more sources
Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity [PDF]
, 2009 L1-CAM (L1 cell-adhesion molecule), or more simply L1, plays an important role in the progression of human carcinoma. Overexpression promotes tumour-cell invasion and motility, growth in nude mice and tumour metastasis.
Altevogt, Peter +6 more
core +2 more sources
Innate immunity protein IFITM3 modulates γ-secretase in Alzheimer disease
Nature, 2020 Innate immunity is associated with Alzheimer’s disease1, but the influence of immune activation on the production of amyloid-β is unknown2,3. Here we identify interferon-induced transmembrane protein 3 (IFITM3) as a γ-secretase modulatory protein, and ...
J. Hur +30 more
semanticscholar +1 more source
Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer's disease.
Neuropharmacology, 2021 Alzheimer's disease (AD) is the most common dementia, and no disease-modifying therapeutic agents are currently available. BDNF/TrkB signaling is impaired in AD and is associated with prominent delta-secretase (δ-secretase, also known as asparaginyl ...
Jianming Liao +8 more
semanticscholar +1 more source
Structural basis of γ-secretase inhibition and modulation by small molecule drugs.
Cell, 2020 Development of γ-secretase inhibitors (GSIs) and modulators (GSMs) represents an attractive therapeutic opportunity for Alzheimer's disease (AD) and cancers. However, how these GSIs and GSMs target γ-secretase has remained largely unknown.
Guanghui Yang +5 more
semanticscholar +1 more source
The substrate repertoire of γ-secretase/presenilin.
Seminars in Cell and Developmental Biology, 2020 The intramembrane protease γ-secretase is a hetero-tetrameric protein complex with presenilin as the catalytic subunit and cleaves its membrane protein substrates within their single transmembrane domains.
Gökhan Güner, S. Lichtenthaler
semanticscholar +1 more source
Frontiers in Neuroscience, 2018 The overwhelming majority of dominant mutations causing early onset familial Alzheimer’s disease (EOfAD) occur in only three genes, PSEN1, PSEN2, and APP.
Amanda L. Lumsden +7 more
doaj +1 more source
Ectodomain shedding of the amyloid precursor protein: Cellular control mechanisms and novel modifiers [PDF]
, 2006 Proteolytic cleavage in the ectodomain of the amyloid precursor protein (APP) is a key regulatory step in the generation of the Alzheimer's disease amyloid-beta (A beta) pepticle and occurs through two different protease activities termed alpha- and beta-
Lichtenthaler, Stefan F.
core +1 more source
Synaptic and endosomal localization of active gamma-secretase in rat brain. [PDF]
PLoS ONE, 2010 A key player in the development of Alzheimer's disease (AD) is the gamma-secretase complex consisting of at least four components: presenilin, nicastrin, Aph-1 and Pen-2.
Susanne Frykman +7 more
doaj +1 more source